Treating Acute Leukemias
in Latin America

Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases


This 2-day virtual program offers a comprehensive overview of the latest clinical updates and novel treatment strategies for acute leukemia, presented by experts. Attendees will have the opportunity to gain knowledge on optimal treatment of patients with leukemia, join patient case-based discussions, and interact with experts.

Date and Location

June 19–20, 2024, Webinar


Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Naval Daver

Naval Daver, MD

MD Anderson Cancer Center, Houston, TX, USA


Roberta Demichelis

Roberta Demichelis, MD

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
Mexico City, Mexico

Jae Park

Jae Park, MD

Memorial Sloan Kettering Cancer Center,
New York, NY

Fabio Santos

Fabio Pires S. Santos, MD, PhD

Centro de Oncologia e Hematologia Dayan-Daycoval from Hospital Israelita Albert Einstein and BMT Attending at Hospital BP – Beneficência Portuguesa,
São Paulo, Brazil

Phillip Sheinberg

Phillip Scheinberg, MD, PhD

Hospital A Beneficencia Portuguesa, São Paulo, Brazil


This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with acute leukemia in various countries within the LATAM region.

Day 1: Follow interactive presentations and case-based discussions on the latest updates for ALL and AML prognosis and management, including the role of MRD, risk stratification, and long-term safety considerations, and engage with the faculty in panel discussions on optimal treatment, patient access, and regional challenges across the LATAM region.

Day 2: Join to learn more about current approaches for relapsed ALL and AML, considerations for AYA ALL management (including case-based discussions), and the evolving role of transplantation, and interact with faculty during a panel discussion on how first-line therapy influences subsequent treatment.

Day 1: Virtual Plenary Sessions
Wednesday, June 19, 2024
5.00 PM – 8.00 PM UTC -5 (Houston)
7.00 PM – 10.00 PM UTC -3 (Brasilia/Buenos Aires)

Time (UTC -3) Topic Presenter
7.00 PM – 7.10 PM Welcome and meeting overview; introduction to the voting system Elias Jabbour
7.10 PM – 7.25 PM Latest achievements and developments in ALL and AML Elias Jabbour
7.25 PM – 7.40 PM Review of prognostic value of MRD in ALL and AML Jae Park
7.40 PM – 7.50 PM Best practices for first-line treatment in ALL Elias Jabbour
7.50 PM – 8.05 PM AYA patients with ALL: What is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults and how we can use this experience in adult patients Roberta Demichelis
8.05 PM – 8.35 PM

ALL case-based panel discussion

  • Case ALL: elderly/frail (8 min + 5-min discussion)
  • Case ALL: AYA (8 min + 5-min discussion)
Roberta Demichelis and
TBD (case presenters)
Panelists: all faculty
8.35 PM – 8.45 PM Break  
8.45 PM – 9.10 PM Genetic characterization and risk stratification of AML, role of FLT3 and IDH in AML, and ​special considerations for young and fit patients​ Naval Daver
9.10 PM – 9.25 PM Therapeutic approaches in high-risk and frail patients with AML​ Phillip Scheinberg
9.25 PM – 9.50 PM Panel discussion: Open questions in ALL and AML – regional challenges (transplant, CAR T, studies, and other)​ Elias Jabbour and all faculty​
9.50 PM – 10.00 PM Session close​ Elias Jabbour

Day 2: Virtual Plenary Sessions
Thursday, June 20, 2024
5.00 PM – 8.00 PM UTC -5 (Houston) 
7.00 PM – 10.00 PM UTC -3 (Brasilia/Buenos Aires)

Time (UTC -3) Topic Presenter
7.00 PM – 7.10 PM Welcome to Day 2 Naval Daver
7.10 PM – 7.30 PM Current treatment options for relapsed ALL in adult and elderly patients Elias Jabbour
7.30 PM – 7.50 PM Long-term safety considerations for leukemias (focus on ALL) Jae Park
7.50 PM – 8.10 PM Current and future role of transplantation in acute leukemias in Latin America Phillip Scheinberg
8.10 PM – 8.20 PM Break  
8.20 PM – 8.40 PM Current treatment options for relapsed AML in adult and elderly patients Fabio Santos
8.40 PM – 9.10 PM

AML case-based panel discussion

  • Case AML: young high-risk (8 min + 5-min discussion)
  • Case AML: elderly (8 min + 5-min discussion)
Fabio Santos and
TBD (case presenters)
All faculty
9.10 PM – 9.50 PM

Panel discussion: How treatment in first line influences further approaches in ALL and AML

  • Will CAR T and bispecifics change the treatment landscape?
  • Role of HSCT – is it still necessary?
  • What does the future look like? Adoption of therapies and evolving standards of care in LATAM
Naval Daver and all faculty
9.50 PM – 10.00 PM Session close Navel Daver